Showing papers in "Maturitas in 1987"

TL;DR: Data is presented on the changes in menstrual status that occurred over the period of the study and relating these changes in menstruation to a woman's age and symptom experience.

TL;DR: Some alterations in endocrine function were detected prior to the cessation of menstrual periods and there were changes in prolactin, cortisol, TSH and triiodothyronine in relation to menopausal status as well as in ovarian steroids and gonadotrophins.

TL;DR: It was concluded that Org OD 14 is an effective and safe new preparation for the treatment of climacteric patients and had a beneficial effect on mood and libido.

TL;DR: It was concluded that studies on medication for climacteric complaints should not only be placebo-controlled, but also be of at least 8 to 12 wk duration for proper evaluation.

TL;DR: The clinical efficacy of Org OD 14 treatment in post-menopausal symptoms was confirmed, as well as its lack of or only transient effect on plasma lipids and lipoproteins, suggesting that the two steroids have different modes of action.

TL;DR: Sixteen post-menopausal women who had never previously received any hormonal treatment applied Oestrogel cream 1.5 mg/day percutaneously for 1 yr showed a strong correlation between the change in skin collagen content (in both the abdomen and the thigh) and the originalskin collagen content, indicating that thechange in collagen content in response to oestrogen therapy is dependent on the original level.

TL;DR: Org OD 14 provides a new, efficient and safe means of treating the post-menopausal syndrome and had a significantly better effect on hot flushes and sweating at all stages of assessment.

TL;DR: A novel steroid was found to possess concomitant weak oestrogenic, androgenic and progestational activities and studies of the metabolites of Org OD 14 in rats suggested that these are involved in the complex endocrinological properties displayed by the compound.

TL;DR: The role of androgens, melatonin, thymosin, metabolic hormones (growth hormone, thyroid hormone(s), insulin, glucocorticosteroids) and prostaglandins in the pathobiology of breast cancer is poorly understood.

TL;DR: The data suggest that both of these oestradiol/progestogen combinations are clinically as effective and well-tolerated as oest radiol alone, but that combined oest Radiol/medroxyprogesterone acetate causes fewer adverse lipid metabolic effects than the oestRadiol/LNG combination.

TL;DR: Org OD 14 is an effective and safe compound for the treatment of climacteric syndrome and a beneficial effect on clinical parameters was seen following Org OD 13 treatment.

TL;DR: Findings indicate that Org OD 14 displays no adverse effects on coagulation, while changes in fibrinolysis seem to be beneficial for post-menopausal women.

TL;DR: The results suggest that differences at a very early stage of the adrenal steroidogenesis may influence calcium homeostasis in the post-menopausal woman.

TL;DR: The mean symptom scores were rapidly and similarly reduced in both treatment groups, and remained low throughout the study and were not significantly different from pre-menopausal values.

TL;DR: It is concluded that treatment with sequentially combined oestrogen and progestogen, using norethisterone acetate in combination with 17 beta-oestradiol in clinically relevant doses, does not produce any adverse effects on serum lipids or lipoproteins.

TL;DR: The relationships among sex steroids, sex hormone binding globulin (SHBG) and vertebral bone density as measured by computerized tomography were studied in 18 post-menopausal women and a significant negative correlation was found between SHBG binding capacity (SH BG-BC) and bone density.

TL;DR: No significant difference was found between the effects of Org OD 14 and placebo with regard to any clotting factors at any time interval, although factor VII and factor X levels were consistently lower in the OD 14 group than in the placebo group.

TL;DR: By the end of the sixth session of therapy, most women showed a significant improvement in their main complaint, accompanied by improvements in general symptoms and personal adjustment, in what might otherwise be considered a potentially unresponsive group of women.

TL;DR: The study of the hormonal content of fluid aspirated from gross breast cysts should help elucidate the pathophysiology of breast disease and reveal excellent bioactivity as measured by testosterone production in Leydig cell cultures.

TL;DR: Combination oestrogen-progestogen therapy is recommended for hormone replacement treatment, even in women who have had a hysterectomy, because it will reduce the risk for breast cancer in some women.

TL;DR: It was concluded that it is not possible to make general statements regarding the effects of sex steroids on FT4 levels.

TL;DR: The findings indicate that the higher plasma fibrinogen and triglyceride concentrations and the lower HDL-cholesterol levels observed in women after the menopause might be associated with haemorrheological changes, which might be partly responsible for the increased incidence of cardiovascular diseases in post-menopausal women.

TL;DR: Five oral methods of hormone replacement therapy were prescribed to groups of healthy post-menopausal women and their effects on a group of liver function tests were examined and no evidence of deterioration in liver function was noted.

TL;DR: The results indicate that endometrial proliferation during post-menopausal oestrogen replacement therapy can probably be prevented by the continuous addition of a very low dose of progestogen.

TL;DR: It was able to demonstrate that E1S may cross the splanchnic area unaltered, since its conversion to E1 and E2 was similar after administration by each of the routes investigated.

TL;DR: While screening and detection programmes for breast carcinoma are not cost-effective, these intensive surveillance procedures do allow the early identification of high-risk individuals with the disease and the formulation of screening programmes which incorporate major and minor risk determinants may enhance the effectiveness of efforts to achieve diagnosis at a prognostically favourable stage of disease.

TL;DR: Monitoring of hypertensive women selected among the outpatients attending the Menopause Clinic at Bologna University made it possible to identify a group of climacteric outpat patients at higher cardiovascular risk whose suitability for antihypertensive treatment could be assessed.

TL;DR: It is concluded that, when used in combination with conjugated equine oestrogens, changing from norgestrel, 0.15 mg/day, to dydrogesterone, 10 mg/ day, does not lead to any significant improvement in lipoprotein profile.

TL;DR: The levels of ApoA1 were found to have increased after the 6-week treatment periods using each of those dosages, the increase being most pronounced after treatment with 4 mg E2V, while ApoB concentrations decreased at both dosage levels.